Cargando...
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...
Gardado en:
| Publicado en: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7766528/ https://ncbi.nlm.nih.gov/pubmed/33339404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120470 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|